Look back at pharma news in the week to March 12, 2021

14 March 2021

By Barbara Obstoj-Cardwell. Editor

Last week, news related to COVID-19 included US pharma giant Merck & Co and biotech partner Ridgeback Biotherapeutics releasing encouraging mid-stage data on molnupiravir, their antiviral treatment. Producing negative news, CytoDyn reported Phase III data on its COVID-10 candidate Vyrologix (leronlimab) in COVID-19. Elsewhere, US biotech bluebird bio released new analyses relating to LentiGlobin in cell therapy programs that the US Food and Drug Administration put on clinical hold due to a possible link with a case of acute myeloid leukemia (AML). Also of note, after a long wait, AVEO Oncology last Wednesday finally gained FDA approval for its bladder cancer drug Fotivda (tivozanib).

Molnupiravir’s big day draws near

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK